3306-62-5 | 2-Aminobenzenesulfonamide

Packsize	Purity	Availability	Price	Discounted Price
1g	98%	in stock	$12.00	$9.00
5g	98%	in stock	$20.00	$14.00
100g	≥ 98% (HPLC)	in stock	$352.00	$246.00
250g	≥ 98% (HPLC)	in stock	$749.00	$524.00

Description

• Catalog Number: AB49692
• Chemical Name: 2-Aminobenzenesulfonamide
• CAS Number: 3306-62-5
• Molecular Formula: C6H8N2O2S
• Molecular Weight: 172.2049
• MDL Number: MFCD00007932
• SMILES: Nc1ccccc1S(=O)(=O)N
• NSC Number: 36945

Computed Properties

• Complexity: 219
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 11
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 1
• XLogP3: 0.2

Literature

• Molecular cloning, characterization, and inhibition studies of a β-carbonic anhydrase from Malassezia globosa, a potential antidandruff target.

  Journal of medicinal chemistry 20120412

• Cloning, characterization and sulfonamide inhibition studies of an α-carbonic anhydrase from the living fossil sponge Astrosclera willeyana.

  Bioorganic & medicinal chemistry 20120215

• Label-free detection of protein binding with multisine SPR microchips.

  Lab on a chip 20111221

• Inhibition studies of the β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium with sulfonamides and sulfamates.

  Bioorganic & medicinal chemistry 20110815

• A new β-carbonic anhydrase from Brucella suis, its cloning, characterization, and inhibition with sulfonamides and sulfamates, leading to impaired pathogen growth.

  Bioorganic & medicinal chemistry 20110201

• Carbonic anhydrase inhibitors. Inhibition studies with anions and sulfonamides of a new cytosolic enzyme from the scleractinian coral Stylophora pistillata.

  Bioorganic & medicinal chemistry letters 20110115

• 3-(6-Bromo-4-oxo-4H-chromen-3-yl)-3,4-dihydro-2H-1,2,4-benzothia-diazine-1,1-dione.

  Acta crystallographica. Section E, Structure reports online 20101201

• Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

  Bioorganic & medicinal chemistry letters 20101101

• 3-(6-Fluoro-4-oxo-4H-chromen-3-yl)-3,4-dihydro-2H-1,2,4-benzothia-diazine-1,1-dione.

  Acta crystallographica. Section E, Structure reports online 20101101

• Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide.

  Journal of medicinal chemistry 20100527

• 3D-QSAR study of benzene sulfonamide analogs as carbonic anhydrase II inhibitors.

  Bioorganic & medicinal chemistry letters 20100515

• Cloning, characterization, and inhibition studies of a beta-carbonic anhydrase from Brucella suis.

  Journal of medicinal chemistry 20100311

• Gene expression signature-based screening identifies new broadly effective influenza a antivirals.

  PloS one 20100101

• Carbonic anhydrase inhibitors. Characterization and inhibition studies of the most active beta-carbonic anhydrase from Mycobacterium tuberculosis, Rv3588c.

  Bioorganic & medicinal chemistry letters 20091201

• Carbonic anhydrase inhibitors. Inhibition studies of a coral secretory isoform by sulfonamides.

  Bioorganic & medicinal chemistry 20090715

• Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides.

  Bioorganic & medicinal chemistry 20090701

• Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.

  Journal of medicinal chemistry 20090514

• Molecular cloning, characterization, and inhibition studies of the Rv1284 beta-carbonic anhydrase from Mycobacterium tuberculosis with sulfonamides and a sulfamate.

  Journal of medicinal chemistry 20090423

• A novel class of allosteric modulators of AMPA/Kainate receptors.

  Bioorganic & medicinal chemistry letters 20090215

• Carbonic anhydrase inhibitors: inhibition of the beta-class enzyme from the yeast Saccharomyces cerevisiae with sulfonamides and sulfamates.

  Bioorganic & medicinal chemistry 20090201

• Hepatitis C virus NS3 protease inhibitors comprising a novel aromatic P1 moiety.

  Bioorganic & medicinal chemistry 20080315

• Carbonic anhydrase inhibitors: cloning, characterization, and inhibition studies of the cytosolic isozyme III with sulfonamides.

  Bioorganic & medicinal chemistry 20071201

• Carbonic anhydrase inhibitors: the beta-carbonic anhydrase from Helicobacter pylori is a new target for sulfonamide and sulfamate inhibitors.

  Bioorganic & medicinal chemistry letters 20070701

• Carbonic anhydrase inhibitors. DNA cloning, characterization, and inhibition studies of the human secretory isoform VI, a new target for sulfonamide and sulfamate inhibitors.

  Journal of medicinal chemistry 20070125

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• Carbonic anhydrase inhibitors: cloning and sulfonamide inhibition studies of a carboxyterminal truncated alpha-carbonic anhydrase from Helicobacter pylori.

  Bioorganic & medicinal chemistry letters 20060415

• QSAR study on topically acting sulfonamides incorporating GABA moieties: a molecular connectivity approach.

  Bioorganic & medicinal chemistry letters 20060401

• Carbonic anhydrase inhibitors: DNA cloning and inhibition studies of the alpha-carbonic anhydrase from Helicobacter pylori, a new target for developing sulfonamide and sulfamate gastric drugs.

  Journal of medicinal chemistry 20060323

• Carbonic anhydrase inhibitors. The mitochondrial isozyme VB as a new target for sulfonamide and sulfamate inhibitors.

  Journal of medicinal chemistry 20051201

• Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides.

  Bioorganic & medicinal chemistry letters 20050901

• Carbonic anhydrase inhibitors. Inhibition of the transmembrane isozyme XII with sulfonamides-a new target for the design of antitumor and antiglaucoma drugs?

  Bioorganic & medicinal chemistry letters 20050215

• Carbonic anhydrase inhibitors. Inhibition of the human cytosolic isozyme VII with aromatic and heterocyclic sulfonamides.

  Bioorganic & medicinal chemistry letters 20050215

• Carbonic anhydrase inhibitors: inhibition of human cytosolic isozyme II and mitochondrial isozyme V with a series of benzene sulfonamide derivatives.

  Bioorganic & medicinal chemistry letters 20041115

• Carbonic anhydrase inhibitors. Inhibition of cytosolic isozyme XIII with aromatic and heterocyclic sulfonamides: a novel target for the drug design.

  Bioorganic & medicinal chemistry letters 20040716

• Carbonic anhydrase inhibitors: the first QSAR study on inhibition of tumor-associated isoenzyme IX with aromatic and heterocyclic sulfonamides.

  Bioorganic & medicinal chemistry letters 20040621

• Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozyme IX with aromatic and heterocyclic sulfonamides.

  Bioorganic & medicinal chemistry letters 20030324

• Carbonic anhydrase inhibitors. A general approach for the preparation of water-soluble sulfonamides incorporating polyamino-polycarboxylate tails and of their metal complexes possessing long-lasting, topical intraocular pressure-lowering properties.

  Journal of medicinal chemistry 20020328

• Carbonic anhydrase inhibitors: synthesis of sulfonamides incorporating dtpa tails and of their zinc complexes with powerful topical antiglaucoma properties.

  Bioorganic & medicinal chemistry letters 20010226